Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

•A phase II artemis trial to evaluate chemoimmunotherapy for thymic carcinoma.•Carboplatin, paclitaxel, lenvatinib, pembrolizumab combined as first-line therapy.•Induction and maintenance therapy for up to 2 years or until PD.•Primary endpoints are objective response rate, secondary survival, and sa...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lung cancer 2024-06, Vol.25 (4), p.389-394
Hauptverfasser:	Okuma, Yusuke, Nomura, Shogo, Sakakibara-Konishi, Jun, Tsukita, Yoko, Murakami, Shuji, Hosomi, Yukio, Tambo, Yuichi, Kogure, Yoshihito, Yoshioka, Hiroshige, Tamiya, Motohiro, Ninomiya, Kiichiro, Iwama, Eiji
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-PD-L Chemotherapy Immune checkpoint inhibitor Lenvatinib Thymic carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!